A BLOOD TEST THAT can predict with 90 percent accuracy if a healthy person will develop mild cognitive impairment (MCI) or Alzheimer’s disease within three years
A BLOOD TEST THAT can predict with 90 percent accuracy if a healthy person will develop mild cognitive impairment (MCI) or Alzheimer’s disease within three years has been discovered and validated by researchers at Georgetown and six other institutions.
The study team explains in the April issue of Nature Medicine (the paper was published online today) how they discovered and then validated a set of 10 lipid biomarkers in the blood that predict both conditions.
The discovery heralds the possible development of earlier treatment options for Alzheimer’s, when therapy could be more effective at slowing or even preventing onset of the disease.
“Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder,” says the study’s corresponding author, Dr. Howard J. Federoff, executive vice president of health sciences at Georgetown University Medical Center.
There is currently no cure or effective treatment for Alzheimer’s disease, which, according to the World Health Organization, is expected to double every 20 years worldwide – from 35.6 million individuals in 2010 to 115.4 million by 2050.
Federoff, also a professor of neurology, explains there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer’s disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process.
“The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention, and biomarkers defining this asymptomatic period are critical for successful development and application of these therapeutics,” says Federoff.
‘MAJOR STEP FORWARD’
“The lipid panel was able to distinguish with 90 percent accuracy these two distinct groups – cognitively normal participants who would progress to MCI or AD within two to three years, and those who would remain normal in the near future,” says Federoff, who also serves as executive dean of the School of Medicine.
Researchers say the panel reveals changes in the breakdown of neural cell membranes resulting in 10 identifiable lipids, or metabolites, circulating in the blood. In particular, two of the 10 metabolites have strong links to the neuropathology of Alzheimer’s.
“We consider our results a major step toward the commercialization of a preclinical disease biomarker test that could be useful for large-scale screening to identify at-risk individuals,” Federoff concludes. “We’re intending to design a clinical trial where we’ll use this panel to identify people at high risk for Alzheimer’s to test a therapeutic agent that might delay or prevent the emergence of the disease.”
The Latest on: New blood test
The Latest on: Biomechanics
via Google News
The Latest on: New blood test
- Driver who caused deadly 3-car crash on I-10 in New Orleans was drunk, police sayon November 18, 2019 at 10:19 am
New Orleans police allege that a drunk driver caused the three-car crash ... While the court documents don’t specify whether Rankin took a breath test, the records say a chemical test sample which he ...
- Could a blood test for breast cancer be on the horizon?on November 18, 2019 at 3:51 am
The panel of nine was correctly positive in 37% and correctly negative in 79%. A blood test for lung cancer treatment Testing for tau: a new blood test for Alzheimer’s disease Breast cancer diagnosed ...
- Immunoglobulin E (IgE) Allergy Blood Tests - Medical Devices Pipeline Assessment, 2019on November 15, 2019 at 4:39 pm
New York, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Immunoglobulin E (IgE) Allergy Blood Tests - Medical Devices Pipeline Assessment, 2019" - ...
- CBR Announces New Pediatric Genetic Screening Test on World Cord Blood Dayon November 15, 2019 at 5:00 am
LOS ANGELES, Nov. 15, 2019 /PRNewswire/ -- Joining in the World Cord Blood Day celebration, CBR, the global leader in newborn stem cell banking, announced today a new genetic service developed over ...
- Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PETon November 14, 2019 at 4:40 pm
REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early ...
- New blood test marks progress in battle against sepsison November 14, 2019 at 9:09 am
A new blood test could save lives in the treatment of sepsis. It assesses five markers in the blood to predict who is at low, medium, and high risk of death. With this knowledge, doctors could start ...
- Researchers develop, test new blood assay that predicts patients at risk of death from sepsison November 14, 2019 at 8:47 am
The investigators also provide corroborating evidence that children with higher risk of mortality from sepsis also have higher bacterial loads in their blood. Wong said the research team continues to ...
- Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship withon November 14, 2019 at 8:05 am
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET * Topline results expected before the end of Q1/2020 REHOVOT, Israel ...
- New Test Could Determine Who Needs Blood Pressure Medicationon November 13, 2019 at 2:44 pm
Frisco's Lone Star High Lockdown Lifted Preventive cardiology researchers at UT Southwestern Medical Center believe that a new blood test for protein biomarkers could identify these individuals. Their ...
- New blood test for protein biomarkers could identify people in need of treatmenton November 11, 2019 at 11:21 am
Preventive cardiology researchers at UT Southwestern Medical Center believe that a new blood test for protein biomarkers could identify these individuals. Their new study, now published in Circulation ...
via Bing News